Sanofi to expand immunology offerings with Blueprint Medicines

finance.yahoo.com/news/sanofi-expand-immunology-offerings-blueprint-145447705.html

In This Article:
Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline with rare disease treatments.
The acquisition includes Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the US and…

This story appeared on finance.yahoo.com, 2025-06-02 14:54:47.
The Entire Business World on a Single Page. Free to Use →